clascoterone topical
Selected indexed studies
- Guidelines of care for the management of acne vulgaris. (J Am Acad Dermatol, 2024) [PMID:38300170]
- Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. (JAMA Dermatol, 2020) [PMID:32320027]
- Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne. (Ann Pharmacother, 2021) [PMID:33533262]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Guidelines of care for the management of acne vulgaris. (2024) pubmed
- Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. (2020) pubmed
- Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne. (2021) pubmed
- Topical Clascoterone for Acne Vulgaris. (2022) pubmed
- Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years. (2021) pubmed
- The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis. (2024) pubmed
- Clascoterone: First Approval. (2020) pubmed
- Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist. (2021) pubmed
- Clascoterone Stability When Combined with Topical Acne Medications In Vitro. (2025) pubmed
- Is There a Clinically Relevant Risk of Hyperkalemia with Topical Clascoterone Treatment? (2023) pubmed